IP Library Granted Patent US 9,802,999
Granted Patent B2
US 9,802,999 · App. 14/439,896 · Granted Oct 31, 2017

Fusion proteins for the treatment of allergic diseases

Inventors: Maaike Maria Barbara Wilhelmina Dooper (Notteroy, NO); Bjarne Bogen (Snaroya, NO); Heidi Ragnhild Myrset (Fetsund, NO)
Assignee: VETERINAERINSTITUTTET
C07K14/75C07K14/415C07K14/43509C07K14/43531A61K39/00C07K2319/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,802,999
App. No.
14/439,896
Granted
Oct 31, 2017
Kind
B2
Abstract

The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the targeting unit is a FGL-2 C-terminal peptide according to SEQ ID no 1. Provided herein are also uses of said fusion protein as a vaccine for treating allergy, such as shrimp, peanut or mite allergy, as well as a vaccine composition and methods for producing such fusion proteins.

Claims (23)

1. A fusion protein comprising a first peptide and a second peptide optionally linked together with a linker, wherein the first peptide is an allergen and the second peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:1 and sequences that are at least 95% identical to SEQ ID NO:1.

2. The fusion protein according to claim 1 , wherein the allergen is shrimp tropomyosin Pan b 1 (SEQ ID no 15) or parts or fragments thereof.

3. The fusion protein according to claim 2 , wherein parts or fragments of shrimp tropomyosin comprises a sequence according to any one of SEQ ID no 4, 5, 6, 7, and 8.

4. The fusion protein according to claim 1 , wherein the allergen is shrimp tropomyosin peptide 5 (P5) (SEQ ID no 8).

5. The fusion protein according to claim 1 , wherein the allergen is shrimp tropomyosin peptide 1 (P1) (SEQ ID no 4).

6. The fusion protein according to claim 1 , wherein the allergen is P5 (SEQ ID no 8) and the linker is RADAAP (SEQ ID no 12).

7. The fusion protein according to claim 1 , wherein the allergen is P1 (SEQ ID no 4) and the linker is RADAAP (SEQ ID no 12).

8. The fusion protein according to claim 1 , wherein the allergen is a peanut allergen according to SEQ ID no 55 or a homologue thereof having least about 95%, 96%, 97%, 98% or 99% identity to SEQ ID no 55.

9. The fusion protein according to claim 1 , wherein the allergen is a mite allergen according to SEQ ID no 56 or a homologue thereof having least about 95%, 96%, 97%, 98% or 99% identity to SEQ ID no 56.

10. The fusion protein according to claim 1 , wherein the allergen is a mite allergen according to SEQ ID no 57 or a homologue thereof having least about 95%, 96%, 97%, 98% or 99% identity to SEQ ID no 57.

11. The fusion protein according to claim 1 , wherein said linker is RADAAP (SEQ ID no 12).

12. A vaccine composition comprising the fusion protein of claim 1 .

13. A method for preparing a fusion protein according of claim 1 , comprising

the steps of:

a) providing an isolated first allergen peptide or the nucleotide sequence thereof;

b) providing an isolated second targeting unit peptide or the nucleotide sequence thereof, wherein the second peptide or the nucleotide sequence thereof is selected from the group consisting of a FGL-2 C-terminal peptide consisting of SEQ ID NO:1, sequences that are at least 95% identical to SEQ ID NO:1, a polynucleotide sequence encoding the peptide consisting of SEQ ID NO:1, and a polynucleotide sequence encoding sequences that are at least 95% identical to SEQ ID NO:1;

c) optionally providing a peptide linker or the nucleotide sequence encoding the peptide linker;

d) fusing said isolated first allergen peptide or the nucleotide sequence thereof of a), with said isolated second targeting unit peptide or the nucleotide sequence thereof of b), optionally spaced apart by the linker of c); and

e) optionally isolating said fusion protein.

14. The method according to claim 13 , wherein said isolated allergen is selected from the group consisting of SEQ ID no 4, SEQ ID no 5, SEQ ID no 6, SEQ ID no 7, SEQ ID no 8, SEQ ID no 55, SEQ ID no 56, and SEQ ID no 57.

15. The method according to claim 13 , wherein the linker is selected from the group consisting of SEQ ID no 12 and SEQ ID no 46.

16. A method for inhibiting, preventing and/or treating allergy, comprising administering an effective amount of a fusion protein of claim 1 to a subject in need thereof.

17. The method of claim 16 , wherein said allergy is selected from the group consisting of a shrimp allergy, a peanut allergy, and a mite allergy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2015
From: DOOPER, MAAIKE MARIA BARBARA WILHELMINA; BOGEN, BJARNE; MYRSET, HEIDI RAGNHILD
To: VETERINAERINSTITUTTET
Reel/Frame 036206/0025 →
Priority Claims (1)
CA 2794051 · Nov 1, 2012 · national
Continuity (2)
Continuation 13666023 · Nov 1, 2012
Related Publication 20150299294A1 · Oct 22, 2015